These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12675215)

  • 1. An interim analysis of phase I clinical trial of MCC-465, a doxorubicin (DXR) encapsulated in PEG-immunoliposome, in patients with metastatic stomach cancer.
    Matsumura Y
    Adv Exp Med Biol; 2003; 519():179-93. PubMed ID: 12675215
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.
    Matsumura Y; Gotoh M; Muro K; Yamada Y; Shirao K; Shimada Y; Okuwa M; Matsumoto S; Miyata Y; Ohkura H; Chin K; Baba S; Yamao T; Kannami A; Takamatsu Y; Ito K; Takahashi K
    Ann Oncol; 2004 Mar; 15(3):517-25. PubMed ID: 14998859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial.
    Cascinu S; Galizia E; Labianca R; Ferraù F; Pucci F; Silva RR; Luppi G; Beretta GD; Berardi R; Scartozzi M
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):37-43. PubMed ID: 20821330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
    Grenader T; Goldberg A; Gabizon A
    Anticancer Drugs; 2010 Oct; 21(9):868-71. PubMed ID: 20679886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucocutaneous toxicity induced by pegylated liposomal doxorubicin: a single-institution, retrospective case series.
    Vaccaro M; Santarpia M; Calapai G; Mannucci C; Borgia F; Altavilla G; Cannavò SP
    Br J Dermatol; 2017 Feb; 176(2):507-509. PubMed ID: 27291307
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
    Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
    Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated liposomal doxorubicin in platinum-treated recurrent or metastatic cervical carcinoma.
    Ferrandina G; Lorusso D; Longo R; Testa AC; Scambia G
    Gynecol Oncol; 2005 Aug; 98(2):332-3. PubMed ID: 15907985
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
    Ishida T; Atobe K; Wang X; Kiwada H
    J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial.
    Falandry C; Brain E; Bonnefoy M; Mefti F; Jovenin N; Rigal O; Guillem O; El Kouri C; Uwer L; Abadie-Lacourtoisie S; Cretin J; Jacquin JP; Paraiso D; Freyer G
    Eur J Cancer; 2013 Sep; 49(13):2806-14. PubMed ID: 23735702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer.
    Murphy CG; Khasraw M; Seidman AD
    Breast Cancer Res Treat; 2010 Jul; 122(1):177-9. PubMed ID: 20458530
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
    Ren S; Li C; Dai Y; Li N; Wang X; Tian F; Zhou S; Qiu Z; Lu Y; Zhao D; Chen X; Chen D
    J Pharm Pharmacol; 2014 Sep; 66(9):1231-9. PubMed ID: 24716458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution.
    Bernardi D; Errante D; Stefani M; Salvagno L
    Breast; 2010 Dec; 19(6):549-50. PubMed ID: 20542696
    [No Abstract]   [Full Text] [Related]  

  • 17. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
    Alba E; Ruiz-Borrego M; Margelí M; Rodríguez-Lescure A; Sánchez-Rovira P; Ruiz A; Mel-Lorenzo JR; Ramos-Vázquez M; Ribelles N; Calvo E; Casado A; Márquez A; Vicente D; García-Sáenz JA; Martín M
    Breast Cancer Res Treat; 2010 Jul; 122(1):169-76. PubMed ID: 20361253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.
    Constantinidou A; Jones RL; Scurr M; Al-Muderis O; Judson I
    Eur J Cancer; 2009 Nov; 45(17):2930-4. PubMed ID: 19767198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥ 70 years).
    Basso U; Roma A; Brunello A; Falci C; Fiduccia P; Banzato A; Bononi A; Gusella M; Vamvakas L; Zagonel V; Monfardini S
    J Geriatr Oncol; 2013 Oct; 4(4):340-5. PubMed ID: 24472477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
    Kouroussis Ch; Androulakis N; Vamvakas L; Kalykaki A; Spiridonakou S; Kentepozidis N; Saridaki Z; Xiropoulou E; Georgoulias V
    Oncology; 2005; 69(3):202-7. PubMed ID: 16127289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.